These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 3051084)

  • 1. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
    Herlihy OM; Barrow BA; Grant PJ; Levy JC
    Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationships between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes.
    Ferner RE; Antsiferov ML; Kelman AW; Alberti KG; Rawlins MD
    Eur J Clin Pharmacol; 1991; 40(2):163-8. PubMed ID: 2065696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deteriorating beta-cell function in type 2 diabetes: a long-term model.
    Bagust A; Beale S
    QJM; 2003 Apr; 96(4):281-8. PubMed ID: 12651972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidiabetic activity of Chandraprabha vati - A classical Ayurvedic formulation.
    Wanjari MM; Mishra S; Dey YN; Sharma D; Gaidhani SN; Jadhav AD
    J Ayurveda Integr Med; 2016; 7(3):144-150. PubMed ID: 27665674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.
    Tangvarasittichai S
    World J Diabetes; 2015 Apr; 6(3):456-80. PubMed ID: 25897356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An energetic tale of AMPK-independent effects of metformin.
    Miller RA; Birnbaum MJ
    J Clin Invest; 2010 Jul; 120(7):2267-70. PubMed ID: 20577046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
    Salpeter SR; Greyber E; Pasternak GA; Salpeter EE
    Cochrane Database Syst Rev; 2010 Apr; 2010(4):CD002967. PubMed ID: 20393934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of biguanide in therapy of diabetes mellitus].
    Haupt E; Panten U
    Med Klin (Munich); 1997 Aug; 92(8):472-9, 505. PubMed ID: 9340472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Problems and pitfalls of sulphonylurea therapy in older patients.
    Robertson DA; Home PD
    Drugs Aging; 1993; 3(6):510-24. PubMed ID: 8312676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.
    Melander A; Bitzén PO; Faber O; Groop L
    Drugs; 1989 Jan; 37(1):58-72. PubMed ID: 2651086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No glucotoxicity after 53 hours of 6.0 mmol/l hyperglycaemia in normal man.
    Flax H; Matthews DR; Levy JC; Coppack SW; Turner RC
    Diabetologia; 1991 Aug; 34(8):570-5. PubMed ID: 1936660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of glipizide on insulin secretion and blood glucose control in patients with non-insulin-dependent diabetes mellitus.
    Bitzén PO; Melander A; Scherstén B; Svensson M; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1992; 42(1):77-83. PubMed ID: 1541320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired beta-cell responses improve when fasting blood glucose concentration is reduced in non-insulin-dependent diabetes.
    Ferner RE; Rawlins MD; Alberti KG
    Q J Med; 1988 Feb; 66(250):137-46. PubMed ID: 3051084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.
    Levy J; Atkinson AB; Bell PM; McCance DR; Hadden DR
    Diabet Med; 1998 Apr; 15(4):290-6. PubMed ID: 9585393
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.